[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Aswan University\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":339},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,14,0,[8,40,69,95,119,140,165,187,208,228,250,272,290,312],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":29,"lastUpdatePostDateStruct":30,"startDateStruct":33,"completionDateStruct":34,"leadSponsor":36,"locationsCount":39},"100645090","comparing-sedatives-for-intracranial-pressure-control-in-traumatic-brain-injury-100645090",false,"NCT07678216","Comparing Sedatives for Intracranial Pressure Control in Traumatic Brain Injury","Effect of Propofol, Midazolam, and Dexmedetomidine on Intracranial Pressure and Clinical Outcomes in Patients With Moderate-to-Severe Traumatic Brain Injury Undergoing Urgent Neurosurgical Intervention","ICP-TBI","Inclusion Criteria:\n\n* Age ≥18 years\n\n  * Moderate to severe traumatic brain injury with post-resuscitation Glasgow Coma Scale (GCS) ≤12\n  * Undergone urgent neurosurgical intervention (craniotomy, craniectomy, or ICP monitor placement) within 24 hours of injury\n  * Admitted to ICU and expected to require continuous sedation\n  * Hemodynamically stable or stabilized (defined as MAP ≥65 mmHg with vasopressor requirement ≤0.1 mcg\u002Fkg\u002Fmin norepinephrine equivalent)\n  * Informed consent obtained from legally authorized representative\n\nExclusion Criteria:\n\n* The Relative refusal to participate in the research.\n* Known allergy or contraindication to propofol, midazolam, or dexmedetomidine\n* Pre-existing neurological disorders (epilepsy, prior stroke, brain tumors, dementia) that may interfere with outcome assessment\n* Severe hepatic dysfunction (Child-Pugh Class C) or acute liver failure\n* Severe renal dysfunction (eGFR \\\u003C30 mL\u002Fmin\u002F1.73m² or requiring renal replacement therapy)\n* Pregnancy or breastfeeding\n* Hemodynamic instability requiring norepinephrine \\>0.1 mcg\u002Fkg\u002Fmin or equivalent vasopressor support\n* Heart rate \\\u003C50 bpm or second\u002Fthird-degree AV block without pacemaker (relative contraindication for dexmedetomidine)\n* Clinical determination of brain death or expected survival \\\u003C24 hours\n* Enrollment in another interventional trial\n* Severe polytrauma requiring ongoing surgical interventions that would interfere with protocol adherence","ALL","18 Years",{"count":20,"type":21},210,"ESTIMATED","INTERVENTIONAL",[24],"NA","The goal of this clinical trial is to compare the effects of propofol, midazolam, and dexmedetomidine on intracranial pressure control and clinical outcomes in adults with moderate-to-severe traumatic brain injury undergoing urgent neurosurgical intervention.\n\nThe main questions it aims to answer are:\n\n* Which sedative agent provides better control of intracranial pressure, assessed by optic nerve sheath diameter (ONSD), during the first 24 hours after neurosurgical intervention?\n* How do the three sedative agents compare in achieving target sedation depth, maintaining hemodynamic stability, and improving short-term clinical outcomes such as ICU mortality, duration of mechanical ventilation, and ICU length of stay?\n\nParticipants will be randomly assigned to receive propofol, midazolam, or dexmedetomidine for 24 hours of continuous sedation. Clinical, hemodynamic, and neurological outcomes will be assessed and compared among the three study groups.",[27],"Moderate-to-Severe Traumatic Brain Injury","NOT_YET_RECRUITING","2026-06-24",{"date":31,"type":32},"2026-07-01","ACTUAL",{"date":31,"type":21},{"date":35,"type":21},"2028-06-01",{"name":37,"class":38},"Aswan University","OTHER",1,{"id":41,"slug":42,"hasResults":11,"nctId":43,"briefTitle":44,"officialTitle":44,"acronym":4,"eligibilityCriteria":45,"healthyVolunteers":11,"sex":46,"minAge":18,"maxAge":47,"enrollmentInfo":48,"targetDuration":4,"studyType":22,"phases":50,"briefSummary":51,"conditions":52,"keywords":58,"overallStatus":60,"whyStopped":4,"lastUpdateSubmitDate":61,"lastUpdatePostDateStruct":62,"startDateStruct":64,"completionDateStruct":66,"leadSponsor":68,"locationsCount":39},"100628828","comparison-of-efficacy-and-safety-of-manual-syringing-versus-pneumatic-pressure-bag-for-blood-transfusion-in-patients-undergoing-cesarean-section-with-major-obstetric-hemorrhage-100628828","NCT07466719","Comparison of Efficacy and Safety of Manual Syringing Versus Pneumatic Pressure Bag for Blood Transfusion in Patients Undergoing Cesarean Section With Major Obstetric Hemorrhage","Inclusion Criteria:\n\n* Women aged 18-45 years undergoing cesarean section\n* Diagnosed major obstetric hemorrhage (blood loss ≥1000 mL or hemodynamic instability requiring transfusion)\n* Written informed consent for participation\n\nExclusion Criteria:\n\n* Pre-existing hemolytic conditions (e.g., sickle cell disease, thalassemia)\n* Known hypersensitivity to blood products\n* Severe baseline coagulopathy (defined as INR \\> 2.0 or Platelet count \\\u003C 50,000\u002Fmm³) or established disseminated intravascular coagulation (DIC) prior to randomization\n* Refusal to receive blood transfusion","FEMALE","45 Years",{"count":49,"type":21},50,[24],"The goal of this clinical trial is to compare the safety and efficacy of manual syringing versus pneumatic pressure bags for blood transfusion in patients experiencing major obstetric hemorrhage during a cesarean section. It will also evaluate the effectiveness of these methods in rapidly stabilizing patient vital signs. The main questions it aims to answer are:Does manual syringing result in a higher incidence of hemolysis (red blood cell destruction) compared to pneumatic pressure bags?Which method is more effective and faster at achieving hemodynamic stability (restoring normal blood pressure, heart rate, and oxygen levels)?Are there differences between the two methods regarding total blood product usage, transfusion-related complications, and the length of hospital stay?Researchers will compare manual syringing (using 20 mL syringes) to pneumatic pressure bags (inflated to 300 mmHg) to determine which is safer and more efficient for emergency transfusions in resource-constrained environments.Participants will:Be women aged 18-45 years undergoing a cesarean section who are diagnosed with major obstetric hemorrhage (blood loss \\>1000 mL or hemodynamic instability).Be randomly assigned to one of two groups to receive their blood transfusion through either the manual syringe method or a pneumatic pressure bag.Receive standard vascular access through multiple peripheral and jugular cannulae.Undergo close monitoring of vital signs to determine the time to stabilization.Provide blood samples at baseline and six hours post-transfusion to measure markers of hemolysis, specifically Lactate Dehydrogenase (LDH) and indirect bilirubin levels.Be monitored for any transfusion-related complications, such as allergic reactions or acute kidney injury, during their hospital stay and for major complications up to 30 days postoperatively",[53,54,55,56,57],"Obstetric Hemostasis","Intravascular Hemolysis","Major Obstetric Hemorrhage","Manual Syringing Transfusion","Pneumatic Pressure Bag Transfusion",[59,56,57,54],"Major Obstetric Hemorrhage,","RECRUITING","2026-03-10",{"date":63,"type":32},"2026-03-12",{"date":65,"type":32},"2025-09-01",{"date":67,"type":21},"2026-04-01",{"name":37,"class":38},{"id":70,"slug":71,"hasResults":11,"nctId":72,"briefTitle":73,"officialTitle":74,"acronym":4,"eligibilityCriteria":75,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":76,"enrollmentInfo":77,"targetDuration":4,"studyType":79,"phases":4,"briefSummary":80,"conditions":81,"keywords":84,"overallStatus":60,"whyStopped":4,"lastUpdateSubmitDate":88,"lastUpdatePostDateStruct":89,"startDateStruct":90,"completionDateStruct":92,"leadSponsor":94,"locationsCount":39},"100545814","renal-resistive-index-as-a-predictor-of-acute-renal-impairment-in-high-risk-patients-100545814","NCT06386796","Renal Resistive Index as a Predictor of Acute Renal Impairment in High-risk Patients","Renal Resistive Index as a Predictor of Acute Renal Impairment in High-risk Patients Admitted to Surgical Intensive Care Unit.","Inclusion Criteria:\n\n* Patients with severe pre-eclampsia and eclampsia.\n* Polytraumatized patients.\n* Patients admitted to ICU with sepsis.\n* Both genders.\n* Patients above 18 years.\n\nExclusion Criteria:\n\n* patients known to have CKD.\n* patients with congenital renal anomalies.\n* patients with renal transplantation.","80 Years",{"count":78,"type":21},100,"OBSERVATIONAL","To study the ability of RRI, measured by bedside Doppler ultrasound, in detecting acute kidney injury in high-risk patients admitted to surgical intensive care unit, Aswan university hospital, compared with renal biomarkers and conventional assessment using urine output and serum creatinine levels.",[82,83],"Acute Kidney Injury","Critical Illness",[85,86,87],"renal resisitive index","surgical ICU","Cystatin C","2026-03-06",{"date":61,"type":32},{"date":91,"type":32},"2024-04-01",{"date":93,"type":21},"2026-10-01",{"name":37,"class":38},{"id":96,"slug":97,"hasResults":11,"nctId":98,"briefTitle":99,"officialTitle":100,"acronym":4,"eligibilityCriteria":101,"healthyVolunteers":102,"sex":17,"minAge":103,"maxAge":104,"enrollmentInfo":105,"targetDuration":4,"studyType":22,"phases":107,"briefSummary":108,"conditions":109,"keywords":4,"overallStatus":60,"whyStopped":4,"lastUpdateSubmitDate":111,"lastUpdatePostDateStruct":112,"startDateStruct":114,"completionDateStruct":116,"leadSponsor":118,"locationsCount":39},"100618346","impact-of-health-education-on-knowledge-attitude-and-practice-of-post-exposure-prophylaxis-100618346","NCT07330427","Impact of Health Education on Knowledge, Attitude and Practice of Post-exposure Prophylaxis","Impact of Health Education on Knowledge, Attitude and Practice of Post-exposure Prophylaxis Among Health Care Workers at Aswan University Hospital, Egypt","Inclusion Criteria:\n\n1. HCWs at the selected departments (physicians, nurses and housekeepers).\n2. Age \\>18 years old and below 60 years old in both Genders.\n3. HCWs which have direct contact with blood and body fluids.\n\nExclusion Criteria:\n\n1. Age\\\u003C18 years old and above 60 years old.\n2. Non-medical staff at Aswan university hospital.\n3. Health care workers which have no contact with blood or body fluids.",true,"19 Years","55 Years",{"count":106,"type":21},340,[24],"Occupational exposure to blood-borne pathogens, such as human immune-deficiency virus (HIV), hepatitis B virus (HBV), and hepatitis C virus (HCV) for healthcare workers through contact with human blood and body fluids has become a major health concern as it poses a risk of transmission of these infectious agents.\n\nAccording to the World Health Organization (WHO) report, about three million HCWs are exposed to blood-borne pathogens each year, of which 170,000 are exposed to HIV infections, 2 million to HBV infections, and 0.9 million to HCV infections. Most of the time, healthcare providers get exposure through the splash of blood or other body fluids into the eyes, nose, or mouth or nonintact skin exposure, and percutaneous injury occurs as a result of a break in the skin caused by a needlestick or sharps contaminated with blood or body fluids",[110],"Post Exposure Prophylaxis","2026-01-04",{"date":113,"type":32},"2026-01-09",{"date":115,"type":32},"2025-06-01",{"date":117,"type":21},"2026-02-01",{"name":37,"class":38},{"id":120,"slug":121,"hasResults":11,"nctId":122,"briefTitle":123,"officialTitle":124,"acronym":4,"eligibilityCriteria":125,"healthyVolunteers":102,"sex":17,"minAge":18,"maxAge":126,"enrollmentInfo":127,"targetDuration":4,"studyType":79,"phases":4,"briefSummary":129,"conditions":130,"keywords":4,"overallStatus":60,"whyStopped":4,"lastUpdateSubmitDate":132,"lastUpdatePostDateStruct":133,"startDateStruct":135,"completionDateStruct":137,"leadSponsor":139,"locationsCount":39},"100617611","correlation-between-vaspin-gene-polymorphism-and-serum-vaspin-levels-in-psoriasis-vulgaris-100617611","NCT07320872","Correlation Between Vaspin Gene Polymorphism and Serum Vaspin Levels in Psoriasis Vulgaris","Correlation Between Vaspin Gene Polymorphism and Serum Vaspin Levels in Psoriasis Vulgaris and Its Relation to Pathogenesis and Risk of the Disease","Inclusion Criteria:\n\n* Newly diagnosed cases or stopped treatment of at least 6 months of psoriasis patients.\n* Pateints with any age and gender.\n\nExclusion Criteria:\n\n* Pregnancy and lactation.\n* Patients with chronic diseases: cardiac diseases, hepatic disorders, chronic renal failure or malignancies.\n* Patients with associated inflammatory disease such as infections and autoimmune diseases.","50 Years",{"count":128,"type":21},60,"Psoriasis is a common immune-mediated inflammatory skin disease affecting at least 100 million individuals worldwide. In Egypt, the prevalence of psoriasis ranges between 0.19% and 3% of the Egyptian people.\n\nIt is associated with poor quality of life, reduced life expectancy and multimorbidity including psoriatic arthritis, obesity and cardiovascular disease.\n\nVaspin (VASP, SERPIN 12) is a recently discovered adipokine that has been isolated from the visceral adipose tissue of a rat model of type 2 diabetes. It is coded by the gene SERPNA12 located on the long arm of chromosome 14q32.13 and consists of six exons and five introns.",[131],"Psoriasis Vulgaris","2025-12-22",{"date":134,"type":32},"2026-01-06",{"date":136,"type":32},"2025-08-10",{"date":138,"type":21},"2026-08-20",{"name":37,"class":38},{"id":141,"slug":142,"hasResults":11,"nctId":143,"briefTitle":144,"officialTitle":144,"acronym":4,"eligibilityCriteria":145,"healthyVolunteers":102,"sex":146,"minAge":147,"maxAge":148,"enrollmentInfo":149,"targetDuration":4,"studyType":79,"phases":4,"briefSummary":151,"conditions":152,"keywords":154,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":156,"lastUpdatePostDateStruct":157,"startDateStruct":159,"completionDateStruct":161,"leadSponsor":163,"locationsCount":164},"100611141","vitamin-d-nerve-growth-factor-and-nerve-conduction-studies-in-adult-male-type-2-diabetic-neuropathy-patients-100611141","NCT07236723","Vitamin D, Nerve Growth Factor and Nerve Conduction Studies in Adult Male Type 2 Diabetic Neuropathy Patients","Inclusion Criteria:\n\n* Adult male patients 40 -65 years' old who have type 2 diabetes mellitus on oral hypoglycemic , non-diabetic healthy subjects of matched age and type 2male diabetic neuropathy patients of matched age .\n\nExclusion Criteria:\n\n* Cardiac patients.\n* Patients who have transient ischemic attack or stroke.\n* Patients with inflammatory rheumatic diseases.\n* Patients with malignant diseases.\n* Hyperparathyroidism.\n* Hypothyroidism.\n* Renal impairment with renal replacement therapy.\n* Liver diseases.\n* Patients on vitamin D supplementation.\n* Patients on vitamin B12 supplementation.","MALE","40 Years","60 Years",{"count":150,"type":21},57,"study the relationship of vitamin d with nerve growth factor level and nerve conduction studies in adult male type 2 diabetic neuropathy patients",[153],"Diabetic Neuropathy",[155],"vitamin d, nerve growth factor and diabetic neuropathy","2025-11-15",{"date":158,"type":32},"2025-11-19",{"date":160,"type":21},"2025-12",{"date":162,"type":21},"2026-12",{"name":37,"class":38},2,{"id":166,"slug":167,"hasResults":11,"nctId":168,"briefTitle":169,"officialTitle":169,"acronym":4,"eligibilityCriteria":170,"healthyVolunteers":102,"sex":46,"minAge":18,"maxAge":47,"enrollmentInfo":171,"targetDuration":4,"studyType":22,"phases":173,"briefSummary":169,"conditions":175,"keywords":177,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":179,"lastUpdatePostDateStruct":180,"startDateStruct":182,"completionDateStruct":184,"leadSponsor":186,"locationsCount":39},"100603755","phase-4-effect-of-a-20-reduction-in-hyperbaric-bupivacaine-dose-on-high-spinal-block-incidence-in-cesarean-delivery-a-risk-stratified-randomized-controlled-trial-100603755","NCT07140640","Effect of a 20% Reduction in Hyperbaric Bupivacaine Dose on High Spinal Block Incidence in Cesarean Delivery: A Risk-Stratified Randomized Controlled Trial.","Inclusion Criteria:\n\n* • Pregnant women aged 18-45 years.\n\n  * ASA physical status II-III.\n\nExclusion Criteria:\n\n* • Twin pregnancies.\n\n  * Contraindications to spinal anesthesia (e.g., coagulopathy, infection).\n  * Patients with incomplete preoperative data for risk stratification.",{"count":172,"type":21},333,[174],"PHASE4",[176],"Cesarean Section Complications",[178],"cesarean-20% hyperbaric bupivacaine","2025-08-22",{"date":181,"type":32},"2025-08-25",{"date":183,"type":21},"2025-09-15",{"date":185,"type":21},"2026-03-30",{"name":37,"class":38},{"id":188,"slug":189,"hasResults":11,"nctId":190,"briefTitle":191,"officialTitle":192,"acronym":4,"eligibilityCriteria":193,"healthyVolunteers":11,"sex":46,"minAge":18,"maxAge":47,"enrollmentInfo":194,"targetDuration":4,"studyType":22,"phases":196,"briefSummary":197,"conditions":198,"keywords":4,"overallStatus":60,"whyStopped":4,"lastUpdateSubmitDate":200,"lastUpdatePostDateStruct":201,"startDateStruct":203,"completionDateStruct":205,"leadSponsor":207,"locationsCount":39},"100601396","use-of-aromatase-inhibitor-before-misoprostol-in-medical-termination-of-miscarriage-100601396","NCT07109947","Use of Aromatase Inhibitor Before Misoprostol in Medical Termination of Miscarriage","Comparison Between the Use of Aromatase Inhibitor Before Misoprostol and Use of Misoprostol Alone in Medical Termination of Miscarriage","Inclusion Criteria:\n\n* Missed or anembryonic pregnancy.\n* Gestational age from 4 weeks to 26 weeks of pregnancy (confirmed by ultrasound scanning on first day of admittance).\n* Hemoglobin level more than 9g\u002Fl.\n* Closed cervix.\n* No product of conception in the cervical canal.\n\nExclusion Criteria:\n\n* Previous attempt to terminate the pregnancy.\n* Molar pregnancy\n* Abnormal uterine lesions such as fibroids or congenital mal formations.\n* Pregnancy despite of intrauterine contraceptive device.\n* Medical disorders as cardiac, renal or hemorrhagic diseases.\n* BMI more than 35 kg\u002Fm2.\n* Known hypersensitivity to any of the medication used.",{"count":195,"type":21},70,[24],"Abortion is one of the most common complications of pregnancy. Missed abortion is a type of abortions, occurs in 15%-20% of clinically diagnosed pregnancies and is defined as the retention of pregnancy products in the uterus for several days or weeks after death of the fetus.",[199],"Miscarriage","2025-07-31",{"date":202,"type":32},"2025-08-07",{"date":204,"type":32},"2025-07-10",{"date":206,"type":21},"2025-12-10",{"name":37,"class":38},{"id":209,"slug":210,"hasResults":11,"nctId":211,"briefTitle":212,"officialTitle":213,"acronym":4,"eligibilityCriteria":214,"healthyVolunteers":102,"sex":17,"minAge":18,"maxAge":147,"enrollmentInfo":215,"targetDuration":4,"studyType":22,"phases":216,"briefSummary":217,"conditions":218,"keywords":4,"overallStatus":60,"whyStopped":4,"lastUpdateSubmitDate":220,"lastUpdatePostDateStruct":221,"startDateStruct":223,"completionDateStruct":225,"leadSponsor":227,"locationsCount":39},"100597123","assessment-of-serum-catestatin-level-in-acne-vulgaris-patients-100597123","NCT07054398","Assessment of Serum Catestatin Level in Acne Vulgaris Patients","Assessment of Serum Catestatin Level in Acne Vulgaris Patients Before and After Treatment With Oral Isotretinoin","Inclusion Criteria:\n\n* Healthy persons of both sexes with moderate and severe acne.\n\nExclusion Criteria:\n\n* Pregnant and lactating women.\n* Immunocompromised patients.\n* Severe anemia.\n* History of chronic liver disease.\n* Hyperlipidemia\n* Non-inflammatory acne conditions.\n* History of neurologic disorders.\n* History of neoplastic disorders.\n* History of cardiac disease.\n* History of systemic acne treatment for at least 4 weeks prior to inclusion and no topical treatments for at least 2 weeks.\n* Cases with known hypersensitivity reaction to isotretinoin.",{"count":128,"type":21},[24],"Acne vulgaris is a persistent inflammatory condition of the pilosebaceous unit, affecting 85% of people between the ages of 12 and 24, it is regarded as one of the most common diseases in teenagers and young adults.\n\nCatestatin, a peptide derived from chromogranin A (CgA), was first discovered in 1997 as an acute nicotinic-cholinergic antagonist. Later, it was determined that CST is a pleiotropic hormone.",[219],"Acne Vulgaris","2025-06-27",{"date":222,"type":32},"2025-07-08",{"date":224,"type":32},"2025-01-10",{"date":226,"type":21},"2026-01-10",{"name":37,"class":38},{"id":229,"slug":230,"hasResults":11,"nctId":231,"briefTitle":232,"officialTitle":232,"acronym":4,"eligibilityCriteria":233,"healthyVolunteers":102,"sex":46,"minAge":234,"maxAge":147,"enrollmentInfo":235,"targetDuration":4,"studyType":22,"phases":237,"briefSummary":238,"conditions":239,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":243,"lastUpdatePostDateStruct":244,"startDateStruct":246,"completionDateStruct":248,"leadSponsor":249,"locationsCount":39},"100581965","comparison-of-maternal-hemodynamics-during-spinal-anesthesia-with-different-cesarean-delivery-positioning-100581965","NCT06857162","Comparison of Maternal Hemodynamics During Spinal Anesthesia with Different Cesarean Delivery Positioning","Inclusion Criteria:\n\n* Pregnant women scheduled for elective cesarean delivery.\n* Age between 18 and 40 years.\n* ASA (American Society of Anesthesiologists) physical status II.\n\nExclusion Criteria:\n\n* Emergency cesarean delivery.\n* Pre-existing cardiovascular disease.\n* Severe preeclampsia or eclampsia.\n* Multiple pregnancies.\n* Known fetal anomalies.","20 Years",{"count":236,"type":21},216,[24],"Cesarean delivery is a common surgical procedure, and maintaining maternal hemodynamic stability during the procedure is crucial for both maternal and fetal outcomes . Hemodynamic instability, such as hypotension following spinal anesthesia, is a frequent complication and can lead to adverse maternal and neonatal outcomes. Traditionally, after spinal anesthesia, women are positioned supine, sometimes with a slight left lateral tilt to mitigate the risk of aortocaval compression . However, recent studies and clinical observations suggest that delayed supine positioning-keeping the patient in a sitting or semi-sitting position for a period following spinal anesthesiamay improve hemodynamic stability. These alternative positions may help to mitigate the abrupt drop in blood pressure commonly seen after spinal anesthesia by allowing for a more gradual redistribution of blood volume . Understanding the optimal positioning strategy could lead to improved clinical protocols that enhance maternal and fetal safety. By comparing immediate supine positioning with delayed supine positioning (in sitting and semi-sitting positions), this study aims to provide evidence on which positioning strategy offers the best hemodynamic outcomes.",[240,241,242],"This Study Aims to Provide Evidence on Which Positioning Strategy Offers the Best Hemodynamic Outcomes","Maternal Hemodynamic","Maternal Positioning During CS","2025-03-15",{"date":245,"type":32},"2025-03-19",{"date":247,"type":21},"2025-04-25",{"date":65,"type":21},{"name":37,"class":38},{"id":251,"slug":252,"hasResults":11,"nctId":253,"briefTitle":254,"officialTitle":254,"acronym":4,"eligibilityCriteria":255,"healthyVolunteers":102,"sex":17,"minAge":256,"maxAge":257,"enrollmentInfo":258,"targetDuration":4,"studyType":22,"phases":260,"briefSummary":261,"conditions":262,"keywords":4,"overallStatus":60,"whyStopped":4,"lastUpdateSubmitDate":264,"lastUpdatePostDateStruct":265,"startDateStruct":267,"completionDateStruct":269,"leadSponsor":271,"locationsCount":39},"100570822","evaluation-the-effect-of-nb-uvb-and-methotrexate-on-the-level-of-serum-gelsolin-in-psoriatic-patients-100570822","NCT06712238","Evaluation The Effect of NB-UVB and Methotrexate on The Level of Serum Gelsolin in Psoriatic Patients","Inclusion Criteria:\n\n* Patients with moderate to severe plaque psoriasis.\n* No restriction of age, race nor occupation.\n\nExclusion Criteria:\n\n* History of psoriasis treatment with systemic and biological agents prior to the study for at least 3 months.\n* Pregnancy and lactation.\n* Infections.\n* Patients with chronic diseases: hepatic disorders, hematologic diseases, chronic renal failure or cancer.","15 Years","65 Years",{"count":259,"type":21},48,[24],"Psoriasis is a common chronic, immune-mediated, skin disease with a significantly negative impact on patients' quality of life. It is one of papulosquamous diseases defined by erythematous plaques with silvery scales.\n\nThe interplay among cytokines released by dendritic, Th1, Th2, and Th17 cells leads to the clinical manifestations seen in psoriasis. Although discovering novel biomarkers for psoriasis is challenging step., it may play an essential role in diagnosis, severity assessment and prediction of treatment outcome and prognosis of the disease",[263],"Psoriatic Conditions","2024-11-26",{"date":266,"type":32},"2024-12-02",{"date":268,"type":32},"2024-06-10",{"date":270,"type":21},"2025-06-10",{"name":37,"class":38},{"id":273,"slug":274,"hasResults":11,"nctId":275,"briefTitle":276,"officialTitle":277,"acronym":4,"eligibilityCriteria":278,"healthyVolunteers":102,"sex":17,"minAge":18,"maxAge":126,"enrollmentInfo":279,"targetDuration":4,"studyType":79,"phases":4,"briefSummary":280,"conditions":281,"keywords":4,"overallStatus":60,"whyStopped":4,"lastUpdateSubmitDate":283,"lastUpdatePostDateStruct":284,"startDateStruct":286,"completionDateStruct":288,"leadSponsor":289,"locationsCount":39},"100568627","tgf--1-expression-related-gene-polymorphism-100568627","NCT06683690","TGF β 1 Expression Related Gene Polymorphism","TGF β 1 Expression Related Gene Polymorphism and Their Association With Clinical Types of Leprosy","Inclusion Criteria:\n\n* Patients of both sexes with leprosy.\n* Age above 18 years.\n* patients on multidrug therapy of leprosy.\n\nExclusion Criteria:\n\n* Patients with other dermatological disease.\n* Patients with leprosy reaction.\n* Pregnancy and lactation.\n* Patients with autoimmune disease.",{"count":128,"type":21},"Leprosy is one of the oldest human infectious diseases. It is a chronic infectious contagious, granulomatous disease caused by intracellular bacillus.\n\nMycobacterium leprae, this chronic granulomatous disease presents symptoms that mainly affected the skin, the nervous system and the reticuloendothelial system, also other systems can be affected, such as the upper respiratory tract, bones and joints, eyes and adrenal glands.\n\nTGF- β is a pleiotropic cytokine that employs several functions on different types of cells. The effect of other cytokines may finally modulate the cellular response in the presence of TGF- β, causing a different effect depending on the activation state of the cell involved. In addition, TGF- β promotes the healing of inflamed tissue through the stimulation and regulation of extracellular matrix by fibroblasts, in addition to inducing the proliferation of endothelial cells required for angiogenesis. Thus, TGF- β is able to regulate the expression of other growth factors, increasing their level of activity.",[282],"Leprosy","2024-11-08",{"date":285,"type":32},"2024-11-12",{"date":287,"type":32},"2024-07-10",{"date":204,"type":21},{"name":37,"class":38},{"id":291,"slug":292,"hasResults":11,"nctId":293,"briefTitle":294,"officialTitle":295,"acronym":4,"eligibilityCriteria":296,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":297,"targetDuration":4,"studyType":22,"phases":298,"briefSummary":299,"conditions":300,"keywords":302,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":304,"lastUpdatePostDateStruct":305,"startDateStruct":307,"completionDateStruct":309,"leadSponsor":311,"locationsCount":4},"100555298","dapagliflozin-in-reducing-epicardial-adipose-tissue-in-heart-failure-with-preserved-ejection-fraction-100555298","NCT06510270","Dapagliflozin in Reducing Epicardial Adipose Tissue in Heart Failure with Preserved Ejection Fraction","Targeting Epicardial Adipose Tissue in Heart Failure with Preserved Ejection Fraction: Exploring the Dapagliflozin Connection","Inclusion Criteria:\n\n1. Age \\>18 years.\n2. Patients with established diagnosis of HFpEF: (1. Signs and Symptoms of Heart Failure. 2. Preserved Ejection Fraction (EF): EF greater than or equal to 50% is generally considered preserved. 3.Echo-cardiography: Evidence of left ventricular hypertrophy (LVH) or Evidence of diastolic dysfunction, such as impaired relaxation or increased stiffness of the left ventricle. 4.Elevated Natriuretic Peptides: serum N-terminal pro-B type natriuretic peptide (NT-proBNP) ≥400 pg\u002FmL or brain natriuretic peptide ≥100 pg\u002FmL can support the diagnosis of HFpEF in the presence of symptoms and other findings).\n3. BMI \\>27Kg\u002Fm2.\n4. Adequate follow-up: Participants must be willing and able to comply with the study protocol and follow-up requirements.\n\nExclusion Criteria:\n\n* 1\\. Age \\<18 years. 2. Type 1 diabetes: Exclude individuals with type 1 diabetes, as dapagliflozin is primarily used for type 2 diabetes management.\n\n  3\\. Significant renal impairment: Exclude participants with severe renal impairment or end-stage renal disease.\n\n  4\\. Severe hepatic impairment: Exclude participants with severe hepatic dysfunction.\n\n  5\\. Pregnancy or breastfeeding: Exclude pregnant or lactating individuals. 6. Patients who underwent Bariateric surgery. 7. BMI\\<27Kg\u002Fm2. 8. Other serious medical conditions: Exclude participants with serious medical conditions that could interfere with the study or confound the results (e.g., cancer, severe infections).\n\n  9\\. Inability to comply: Exclude participants who are unable or unwilling to comply with the study procedures and requirements.",{"count":195,"type":21},[24],"Heart failure with preserved ejection fraction (HFpEF) is becoming the most common cause of heart failure worldwide, in part, driven by a rising prevalence of obesity.\n\nAlthough generalized and visceral adiposity is important in the pathogenesis of obesity-related HFpEF, there is increasing recognition of the potential role of epicardial adipose tissue (EAT) in disease pathogenesis. EAT is metabolically active tissue located directly on the surface of the myocardium underneath the visceral pericardium. By virtue of its anatomical interface with the heart and the lack of fascial separation between the underlying myocardium and epicardial fat, locally secreted adipokines directly bathe the surface of the heart and result in underlying myocardial remodeling.\n\nIts position on the surface of the myocardium allows EAT to directly contribute to an increase in total heart size with stretch of the pericardium and results in relative pericardial restraint with constrictive physiology.\n\nEAT is most commonly measured by echocardiography in the parasternal long axis view perpendicular to the right ventricle (RV) to quantify epicardial fat thickness and this has been correlated with worse haemodynamic derangements and adverse outcomes in HFpEF.\n\nAlternatively, cardiac MRI or CT can provide a more complete volumetric assessment of epicardial fat volume and has also demonstrated associations with adverse outcomes and functional metrics in most but not all HFpEF studies.\n\nVery little is understood about the impact of medical modulation of epicardial fat in HFpEF. The first proven agents to improve heart failure hospitalization and quality of life in HFpEF are the sodium-glucose cotransporter-2 inhibitors (SGLT2i) Although the mechanisms of benefit of these drugs are uncertain, they have demonstrated a reduction in epicardial fat despite only minimal weight loss suggesting a direct lipolytic effect on epicardial fat. The use of SGLT2i has also been associated with reduced incident AF, which may, in part, be due to the reduction in epicardial fat. The diuretic effect of SGLT2i may facilitate a reduction in plasma volume and mechanistic studies have shown that they also promote ventricular mass regression, which may cumulatively decrease pericardial restraint.\n\nBy this work we aims To determine whether the addition of 10 mg of Dapagliflozin to a patient with HFPEF can lead to a decrease in epicardial adipose tissue volume, which is a new approach to managing HFPEF or not.",[301],"Heart Failure with Preserved Ejection Fraction",[303],"HFpEF, Dapagliflozin, epicardial adipose tissue","2024-07-15",{"date":306,"type":32},"2024-07-19",{"date":308,"type":21},"2024-08-01",{"date":310,"type":21},"2025-10-01",{"name":37,"class":38},{"id":313,"slug":314,"hasResults":11,"nctId":315,"briefTitle":316,"officialTitle":317,"acronym":4,"eligibilityCriteria":318,"healthyVolunteers":102,"sex":17,"minAge":319,"maxAge":320,"enrollmentInfo":321,"targetDuration":4,"studyType":22,"phases":323,"briefSummary":324,"conditions":325,"keywords":328,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":332,"lastUpdatePostDateStruct":333,"startDateStruct":334,"completionDateStruct":336,"leadSponsor":338,"locationsCount":4},"100550457","clinical-and-radiographic-evaluation-of-two-matrix-systems-for-restoration-of-class-ii-cavities-in-primary-molars-100550457","NCT06447324","Clinical and Radiographic Evaluation of Two Matrix Systems for Restoration of Class II Cavities in Primary Molars","Assessment of Clinical, Radiographical Efficacy, Operator Ease and Satisfaction and Patient Comfort in Restoring Class II Cavities in Primary Molars With Fender Mate System Versus T-Band System: An in Vivo Study","Inclusion Criteria:\n\n1. Apparently healthy children free from any systemic diseases.\n2. Patients showing Frankel's positive and definitely positive behavior.\n3. Parent willing to participate in the study and signed on informed consent.\n4. Each child has at least two carious primary molars (class II) bilaterally, indicated for composite restoration with criteria as follow: -\n\n   * No history of spontaneous pain or provoked pain.\n   * Fully erupted teeth.\n   * Fully erupted adjacent tooth.\n   * Caries involving two surfaces - proximal and occlusal\n   * Absence of clinical signs or symptoms suggesting a non-vital tooth such as sinus tract, soft tissue swelling, mobility or tenderness to percussion.\n   * No pathological external or internal root resorption.\n\nExclusion Criteria:\n\n1. Patients showing Frankel's negative and definitely negative behavior.\n2. Children having primary molars with:\n\n   * Caries involving less than or more than two surfaces\n   * Extensively damaged teeth\n   * Missing adjacent tooth.\n   * Mobility.\n   * Spaced dentition.","4 Years","9 Years",{"count":322,"type":21},20,[24],"this study aims to evaluate and compare the clinical and radiographical efficacy, operator ease, satisfaction and patient comfort in restoring class II cavities in primary molars using Fender Mate system with T-band system.",[326,327],"Tooth Decay","Tooth Restoration",[329,330,331],"Matrix Systems","Class II Cavities","Primary Molars","2024-06-06",{"date":268,"type":32},{"date":335,"type":21},"2024-07-01",{"date":337,"type":21},"2024-10-30",{"name":37,"class":38},""]